{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:25:43Z","timestamp":1792589143349,"version":"4.5.0"},"reference-count":20,"publisher":"American Association for Cancer Research (AACR)","issue":"12","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bisphosphonates are primarily known for their ability to inhibit osteoclast-mediated bone resorption. They are an indispensable part of therapy for patients with cancers that cause osteolysis. However, there is now a growing body of evidence from preclinical research showing that bisphosphonates also exhibit antitumor activity, both in vitro and in vivo. They can affect molecular mechanisms of tumor cell adhesion, invasion, and proliferation; reinforce the effects of cytotoxic agents in a synergistic manner; and exhibit antiangiogenic and immunomodulatory effects. These preclinical findings reveal exciting ways of optimizing bisphosphonate therapy in oncology to fully exploit their antitumor potential.<\/jats:p>","DOI":"10.1158\/0008-5472.can-05-0264","type":"journal-article","created":{"date-parts":[[2005,9,15]],"date-time":"2005-09-15T21:53:09Z","timestamp":1126821189000},"page":"4971-4974","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":204,"title":["Bisphosphonates and Cancer-Induced Bone Disease: Beyond Their Antiresorptive Activity"],"prefix":"10.1158","volume":"65","author":[{"given":"Philippe","family":"Cle\u0301zardin","sequence":"first","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale Research Unit 664, Laennec School of Medicine, Lyon, France and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank H.","family":"Ebetino","sequence":"additional","affiliation":[{"name":"2Procter and Gamble Pharmaceuticals, Mason, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierrick G.J.","family":"Fournier","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale Research Unit 664, Laennec School of Medicine, Lyon, France and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2005,6,15]]},"reference":[{"key":"2022061621051157600_B1","doi-asserted-by":"crossref","unstructured":"Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Design\u20082003; 9: 2643\u201358.","DOI":"10.2174\/1381612033453640"},{"key":"2022061621051157600_B2","doi-asserted-by":"crossref","unstructured":"Cle\u0301zardin P, Fournier P, Boissier S, Peyruchaud O. In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem\u20082003; 10: 173\u201380.","DOI":"10.2174\/0929867033368529"},{"key":"2022061621051157600_B3","doi-asserted-by":"crossref","unstructured":"Green J. Antitumor effects of bisphosphonates. Cancer\u20082003; 97: 840\u20137.","DOI":"10.1002\/cncr.11128"},{"key":"2022061621051157600_B4","doi-asserted-by":"crossref","unstructured":"Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int\u20082004; 94: 164\u201370.","DOI":"10.1111\/j.1464-4096.2004.04831.x"},{"key":"2022061621051157600_B5","doi-asserted-by":"crossref","unstructured":"Bezzi M, Hasmim M, Bieler G, Dormond O, Ru\u0308egg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death. J Biol Chem\u20082003; 278: 43603\u201314.","DOI":"10.1074\/jbc.M308114200"},{"key":"2022061621051157600_B6","doi-asserted-by":"crossref","unstructured":"Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the action of zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer\u20082003; 88: 1631\u201340.","DOI":"10.1038\/sj.bjc.6600925"},{"key":"2022061621051157600_B7","doi-asserted-by":"crossref","unstructured":"Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model. Clin Cancer Res\u20082004; 10: 4559\u201367.","DOI":"10.1158\/1078-0432.CCR-03-0325"},{"key":"2022061621051157600_B8","unstructured":"Sawada K, Morishige K, Tahara M, et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res\u20082002; 62: 6015\u201320."},{"key":"2022061621051157600_B9","doi-asserted-by":"crossref","unstructured":"Yamagishi S, Abe R, Inagaki Y, et al. Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol\u20082004; 165: 1865\u201374.","DOI":"10.1016\/S0002-9440(10)63239-7"},{"key":"2022061621051157600_B10","doi-asserted-by":"crossref","unstructured":"Kuroda J, Kimura S, Segawa H, et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood\u20082003; 102: 2229\u201335.","DOI":"10.1182\/blood-2003-01-0305"},{"key":"2022061621051157600_B11","doi-asserted-by":"crossref","unstructured":"Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer\u20082005; 113: 364\u201371.","DOI":"10.1002\/ijc.20602"},{"key":"2022061621051157600_B12","unstructured":"Corey E, Brown LG, Quinn JE, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res\u20082003; 9: 295\u2013306."},{"key":"2022061621051157600_B13","doi-asserted-by":"crossref","unstructured":"Michigami T, Hiraga T, Williams PJ, et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat\u20082002; 75: 249\u201358.","DOI":"10.1023\/A:1019905111666"},{"key":"2022061621051157600_B14","doi-asserted-by":"crossref","unstructured":"Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest\u20082004; 114: 623\u201333.","DOI":"10.1172\/JCI200422087"},{"key":"2022061621051157600_B15","unstructured":"Yano S, Zhang H, Hanibuchi M, et al. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice. Clin Cancer Res\u20082003; 9: 5380\u20135."},{"key":"2022061621051157600_B16","unstructured":"Sohara Y, Shimada H, Scadeng M, et al. Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate. Cancer Res\u20082003; 63: 3026\u201331."},{"key":"2022061621051157600_B17","doi-asserted-by":"crossref","unstructured":"Croucher PI, De Raeve H, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res\u20082003; 18: 482\u201392.","DOI":"10.1359\/jbmr.2003.18.3.482"},{"key":"2022061621051157600_B18","doi-asserted-by":"crossref","unstructured":"Hashimoto K, Morishige K, Sawada K, et al. Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. Cancer Res\u20082005; 65: 540\u20135.","DOI":"10.1158\/0008-5472.540.65.2"},{"key":"2022061621051157600_B19","doi-asserted-by":"crossref","unstructured":"Gober HJ, Kistowska M, Angman L, Jeno\u0308 P, Mori L, De Libero G. Human T cell receptor \u03b3\u03b4 cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med\u20082003; 197: 163\u20138.","DOI":"10.1084\/jem.20021500"},{"key":"2022061621051157600_B20","doi-asserted-by":"crossref","unstructured":"Wilhelm M, Kunzmann V, Eckstein S, et al. \u03b3\u03b4 T cells for immune therapy of patients with lymphoid malignancies. Blood\u20082003; 102: 200\u20136.","DOI":"10.1182\/blood-2002-12-3665"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/12\/4971\/2532614\/4971-4974.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/12\/4971\/2532614\/4971-4974.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T14:50:49Z","timestamp":1683211849000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/65\/12\/4971\/518128\/Bisphosphonates-and-Cancer-Induced-Bone-Disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,15]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2005,6,15]]},"published-print":{"date-parts":[[2005,6,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-05-0264","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,15]]}}}